Free Trial
NASDAQ:ARTL

Artelo Biosciences (ARTL) Stock Price, News & Analysis

Artelo Biosciences logo
$1.19
+0.01 (+0.85%)
(As of 10/31/2024 ET)

About Artelo Biosciences Stock (NASDAQ:ARTL)

Key Stats

Today's Range
$1.15
$1.23
50-Day Range
$1.06
$1.31
52-Week Range
$1.00
$1.75
Volume
17,885 shs
Average Volume
34,031 shs
Market Capitalization
$3.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Strong Buy

Company Overview

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Artelo Biosciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
74th Percentile Overall Score

ARTL MarketRank™: 

Artelo Biosciences scored higher than 74% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Artelo Biosciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Artelo Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Artelo Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Artelo Biosciences are expected to grow in the coming year, from ($2.41) to ($1.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Artelo Biosciences is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Artelo Biosciences is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Artelo Biosciences has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Artelo Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    0.85% of the float of Artelo Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Artelo Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Artelo Biosciences has recently decreased by 18.32%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Artelo Biosciences does not currently pay a dividend.

  • Dividend Growth

    Artelo Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.85% of the float of Artelo Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Artelo Biosciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Artelo Biosciences has recently decreased by 18.32%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Artelo Biosciences has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Artelo Biosciences this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added Artelo Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Artelo Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.90% of the stock of Artelo Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 0.87% of the stock of Artelo Biosciences is held by institutions.

  • Read more about Artelo Biosciences' insider trading history.
Receive ARTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ARTL Stock News Headlines

Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
See More Headlines

ARTL Stock Analysis - Frequently Asked Questions

Artelo Biosciences' stock was trading at $1.40 at the beginning of the year. Since then, ARTL shares have decreased by 15.0% and is now trading at $1.19.
View the best growth stocks for 2024 here
.

Artelo Biosciences, Inc. (NASDAQ:ARTL) issued its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.10.

Artelo Biosciences's stock reverse split before market open on Wednesday, August 10th 2022. The 1-15 reverse split was announced on Wednesday, August 10th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artelo Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CrowdStrike (CRWD), Palantir Technologies (PLTR), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/13/2024
Today
10/31/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARTL
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+334.8%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-9,290,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.12 per share

Miscellaneous

Free Float
3,005,000
Market Cap
$3.71 million
Optionable
Not Optionable
Beta
1.36
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:ARTL) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners